Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Ropeginterferon Alfa-2b for Pre-fibrotic Primary Myelofibrosis and DIPSS Low/Intermediate-1 Risk Myelofibrosis

NCT05731245 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT05731245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05731245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Ropeginterferon Alfa-2b for Pre-fibrotic Primary Myelofibrosis and DIPSS Low/Intermediate-1 Risk Myelofibrosis
Lead sponsor
National Taiwan University Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
February 8, 2023
Completion date
October 12, 2026
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pre-fibrotic myelofibrosis